TRAPPC11

TRAPPC11 is a subunit of the multiprotein TRAPP complex that mediates anterograde membrane trafficking, with a particular requirement for cargo exit from the Golgi to the cell surface (PMID:23830518). Disease-causing mutations in its C-terminal domains, including the foie gras and gryzun regions, impair TRAPPC11 binding to other TRAPP components and disrupt Golgi architecture, producing a dual defect in ER-to-Golgi transport and delayed Golgi-to-plasma-membrane exit (PMID:23830518, PMID:31575891). Beyond bulk trafficking, TRAPPC11 is uniquely required among TRAPP subunits for lipid-linked oligosaccharide (LLO) biosynthesis and protein N-glycosylation: its loss reduces LLO levels, drives compensatory up-regulation of the terpenoid (dolichol) pathway, and causes protein hypoglycosylation that phenocopies a stressed unfolded protein response (PMID:26912795). This glycosylation deficit affects specific substrates including the lysosomal membrane glycoproteins LAMP1/LAMP2, ICAM-1, and α-dystroglycan, the last linking TRAPPC11 loss to the dystroglycanopathy spectrum and to N-linked congenital disorders of glycosylation affecting muscle and brain (PMID:23830518, PMID:29855340, PMID:34648194, PMID:38564972). TRAPPC11 deficiency additionally disrupts autophagic flux and mitochondrial ATP production and network architecture, in a domain-dependent manner (PMID:31575891, PMID:37197784). Recessive TRAPPC11 mutations cause a congenital disorder of glycosylation presenting with muscular dystrophy and neuropathology (PMID:29855340, PMID:34648194).

1. 2013 High

   Established TRAPPC11 as a bona fide TRAPP complex subunit and showed that patient mutations act by disrupting complex assembly and Golgi-exit trafficking, defining the molecular basis of disease.

   Evidence Co-immunoprecipitation of TRAPP components and trafficking/Golgi-morphology assays with two patient mutations in fibroblasts

   PMID:23830518

   Open questions at the time

   • Which TRAPP subunits TRAPPC11 directly contacts not resolved
   • No structural model of the binding interface
   • Mechanism linking complex disruption to delayed Golgi exit unknown
2. 2016 High

   Revealed a TRAPPC11-specific role in LLO biosynthesis and N-glycosylation distinct from its trafficking function, connecting TRAPP to the glycosylation machinery.

   Evidence Zebrafish mutant LLO quantification, terpenoid-pathway qRT-PCR, pharmacological phenocopy, and selective siRNA depletion of individual TRAPP subunits in human cells

   PMID:26912795

   Open questions at the time

   • Direct biochemical link between TRAPPC11 and LLO synthesis enzymes not established
   • Mechanism of UPR activation downstream of hypoglycosylation unclear
   • Cause of lipid droplet accumulation not defined
3. 2016 Medium

   Confirmed in an independent patient that reduced full-length TRAPPC11 produces both impaired Golgi arrival and exit alongside LAMP1 hypoglycosylation, reinforcing the dual trafficking/glycosylation phenotype.

   Evidence Western blot, trafficking marker assays, and LAMP1 glycosylation immunofluorescence in patient fibroblasts with a splice mutation

   PMID:27707803

   Open questions at the time

   • Single lab, single patient
   • No reconstitution of LLO/glycosylation defect
   • Residual full-length protein levels not quantitatively linked to phenotype severity
4. 2018 Medium

   Connected TRAPPC11 to the dystroglycanopathies by demonstrating α-dystroglycan hypoglycosylation, broadening the disease classification to include a membrane trafficking gene.

   Evidence Immunofluorescence and western blot for α-dystroglycan in muscle biopsy plus live-cell trafficking in patient fibroblasts

   PMID:29855340

   Open questions at the time

   • Whether α-dystroglycan defect is direct or secondary to general hypoglycosylation unknown
   • Single lab
   • No tissue-specific mechanism for muscle vulnerability
5. 2019 Medium

   Mapped functional contributions to specific TRAPPC11 domains, showing the C-terminus and foie gras domain are required for autophagic flux whereas the Gly980Arg variant spares autophagy, establishing domain-specific roles.

   Evidence Trafficking, glycosylation, and autophagic flux (LC3-II ± bafilomycin) assays across distinct patient variants

   PMID:31575891

   Open questions at the time

   • Molecular mechanism linking TRAPPC11 to autophagic flux unknown
   • Single lab
   • Structural basis for domain-specific effects not determined
6. 2021 Medium

   Extended the glycosylation defect to brain tissue including Purkinje cells and dentate neurons, framing TRAPPC11-opathy as an N-linked CDG with central nervous system involvement.

   Evidence Trafficking assays and IIH6 α-dystroglycan immunofluorescence in muscle biopsy and post-mortem brain plus western blot

   PMID:34648194

   Open questions at the time

   • Neuron-specific mechanism not addressed
   • Single lab
   • Causality between trafficking defect and neuropathology not demonstrated
7. 2023 Low

   Expanded TRAPPC11 function beyond trafficking and glycosylation by linking deficiency to impaired mitochondrial ATP production and altered network architecture.

   Evidence Mitochondrial ATP production assays and network imaging in patient-derived cells

   PMID:37197784

   Open questions at the time

   • Single lab, single study with limited mechanistic follow-up
   • Whether mitochondrial defect is direct or secondary unknown
   • No molecular pathway connecting TRAPPC11 to mitochondria
8. 2024 Low

   Reaffirmed the CDG classification by showing defective ER-to-Golgi transport with reduced LAMP2 and ICAM-1 glycoprotein expression in a further patient.

   Evidence Membrane trafficking assays and western blot/immunofluorescence for LAMP2 and ICAM-1 in patient fibroblasts

   PMID:38564972

   Open questions at the time

   • Single patient, single lab
   • Replicates prior findings without new mechanistic depth
   • Selectivity of affected glycoproteins not explained

• The biochemical mechanism by which TRAPPC11 uniquely promotes LLO biosynthesis, and how its loss propagates to autophagy and mitochondrial dysfunction, remains unresolved.
• No direct molecular link between TRAPPC11 and dolichol/LLO synthesis enzymes
• No structural model of TRAPPC11 within the TRAPP complex
• Causal chain from trafficking defect to mitochondrial and autophagic phenotypes undefined